This leads to my old question, hopefully one for the forthcoming 2020 virtual AGM - what happened to MPC-300-IV? It showed evidence of action against both Diabetes [T2] and Rheumatoid Arthritis - two very significant markets and it would seem, given MSB's existing PhIII trials are maturing rapidly, bringing it into the home-straight of clinical development, would now seem logical? I know the Prof himself is particularly exited about what he sees as our potentially, most significant application [pre-Covid]. MPC-300-IV would be application to many diseases.
Maybe MSB see Remestemcel-L as a viable stand-in, in those types of applications used "off label"?
- Forums
- ASX - By Stock
- Ulcerative Colitis Clinical Trial
This leads to my old question, hopefully one for the forthcoming...
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.07 |
Change
0.010(0.94%) |
Mkt cap ! $1.218B |
Open | High | Low | Value | Volume |
$1.08 | $1.08 | $1.06 | $725.7K | 677.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 1194 | $1.07 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.08 | 64682 | 9 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 5308 | 1.065 |
20 | 131658 | 1.060 |
8 | 91093 | 1.055 |
7 | 23717 | 1.050 |
5 | 33122 | 1.045 |
Price($) | Vol. | No. |
---|---|---|
1.070 | 16574 | 8 |
1.075 | 55112 | 7 |
1.080 | 103960 | 9 |
1.085 | 118158 | 12 |
1.090 | 231052 | 8 |
Last trade - 11.56am 03/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |